UK to fast-track access to critical medicines


Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April. For diseases where no approved treatment exists, or patients who have exhausted other treatment options, doctors will be permitted to prescribe experimental therapies, which will be supplied by companies to the NHS free of charge.

In order to qualify for the Early Access to Medicines Scheme (EAMS), the product must first be designated as a ‘Promising Innovative Medicine’ by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Then, once the MHRA is satisfied that the drug is safe and the potential benefits outweigh the risks, it will issue an EAMS ‘scientific opinion’. The company will then supply the medicine for free until it is officially approved.

One benefit of the scheme to industry is closer liaison with the regulators over requirements of clinical trial design and manufacturing. Firms will also get much earlier access to data about how their drugs perform in real world settings. While this is not a substitute for comprehensive Phase III clinical studies, it provides a route for small companies, patient groups and charities without the necessary funds to attract investment and bring drugs to the market more easily.

The scheme will not replace the existing pathway to European approval for drugs, and once approved, the medicines will still be subject to value judgements from the UK’s National Institute for Health and Care Excellence (Nice).


Related Content

Merger creates biggest supplier of unlicensed drugs

5 May 2015 Business

news image

Clinigen will buy Idis to consolidate different routes by which doctors can access medicines that are unavailable locally

The hunt for innovation

31 January 2014 Premium contentFeature

news image

Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom

Most Read

First pictures of hydrogen bonds unveiled

26 September 2013 Research

news image

Observation of intermolecular interactions in quinolines could help to settle the nature of this kind of bonding

Copper catalysis overcomes double bond trouble

3 July 2015 Research

news image

Stubbornly stable unactivated internal alkenes become chiral tertiary amine precursors

Most Commented

Collaboration, not competition

29 June 2015 Research

news image

Organic chemist E J Corey talks to Phillip Broadwith about awards, ambition and academic freedom

Z machine puts the squeeze on metallic deuterium

25 June 2015 Research

news image

Pressures similar to those at centre of the Earth forge metallic deuterium in step toward 80-year-old dream of creating metal...